Syndax (SNDX) Q4 2025 earnings review
Dual Blockbuster Launches Drive Surging Revenue and Clear Path to Profitability
Syndax delivered an exceptional Q4, with total revenue jumping 50% sequentially to $68.7 million. This acceleration was fueled by the October FDA approval of Revuforj for NPM1m AML, which tripled its addressable market and drove a 35% spike in prescriptions. Partner-led Niktimvo also proved to be a formidable cash engine, bringing in $19.4 million in high-margin collaboration revenue. While Q4 Net Loss widened slightly to $68.0 million due to clinical trial ramp-ups, management's commitment to capping FY26 cash operating expenses at ~$400 million provides a highly credible, fully-funded path to profitability with their $394 million cash reserve.
🐂 Bull Case
The October 2025 label expansion for Revuforj opens an addressable U.S. market of ~4,500 NPM1m AML patients, vastly larger than the initial 2,000-patient KMT2A market. The 38% sequential revenue growth indicates rapid prescriber adoption.
Incyte's successful launch of Niktimvo (annualizing at over $220M in total sales) translates to pure collaboration profit for Syndax. Syndax's 50% share of net commercial profit leaped 40% QoQ to $19.4 million, serving as a critical funding mechanism.
🐻 Bear Case
Despite promises of a stable expense base, Q4 Operating Expenses spiked to $131.3M (up from $103.3M in Q3), driven by intensive frontline clinical trials. Any revenue hiccups could tighten the profitability runway.
Roughly 33% of Revuforj patients pause treatment for stem cell transplants. If the post-transplant restart rate (currently 35-40%) fails to improve to management's 70-90% target, long-term therapy duration and revenue estimates will compress.
⚖️ Verdict: 🟢🟢
Bullish. It is rare to see a commercial-stage biotech launch two first-in-class assets simultaneously and beat expectations on both. With a capped OpEx runway and revenues accelerating, the risk profile is significantly derisked.
Key Themes
Revuforj Revenue Realigns with Prescriptions
Accelerating. In Q3, Syndax faced questions when Revuforj prescriptions grew 25% but revenue only grew 12% due to gross-to-net adjustments and inventory drawdowns. In Q4, this disconnect was resolved: total prescriptions grew ~35% QoQ to 1,150, and net revenue perfectly mirrored this with a 38% QoQ jump to $44.2 million. The NPM1m approval is clearly translating directly to the top line.
Niktimvo Collaboration Margin Expansion
Accelerating. Syndax books 50% of the net commercial profit from Niktimvo. In Q4, Incyte reported $56.0 million in net revenue (+22% QoQ), while Syndax recognized $19.4 million in collaboration revenue (+40% QoQ). This outsized profit growth demonstrates strong operating leverage as the commercial infrastructure costs become a smaller percentage of total product sales.
Frontline Market Expansion Underway
Stable. To unlock a multi-billion-dollar TAM, Syndax is aggressively pursuing frontline AML indications. The pivotal EVOLVE-2 trial (unfit patients) is already enrolling, and the company successfully initiated the Phase 3 REVEAL-ND trial for newly diagnosed NPM1m AML in November 2025. These dual primary endpoint trials (MRD negative CR and Event Free Survival) could support accelerated approvals.
Q4 Operating Expense Spike
Reversing. Following two quarters of stable total operating expenses (~$103M - $107M), Q4 expenses jumped to $131.3M. R&D alone rose 40% sequentially to $78.6M due to the initiation of frontline trials. While management claims expenses will now stabilize, this Q4 spike sets a higher jumping-off point for 2026 cash burn models.
Future Menin Inhibitor Competition
Stable. Syndax currently enjoys a ~1-year first-mover advantage in the NPM1m AML space. However, as the market expands, defending share against incoming menin inhibitors will be a key challenge, particularly if competitors show differentiated safety profiles (e.g., lower QTc prolongation risk) in real-world settings.
IPF Trial Reaches Enrollment Milestone
Stable. Syndax completed enrollment in MAXPIRe, a Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF), in early 2026. Topline data in Q4 2026 will serve as a massive catalyst. This represents a completely novel mechanism (CSF-1R inhibition of monocytes/macrophages) in a disease characterized by poor standard-of-care options.
Other KPIs
Decelerating cash burn. Syndax burned approximately $62 million in Q4 ($456M down to $394M), an improvement from heavier burn rates earlier in the year. The cash balance, combined with growing revenues, forms the backbone of management's claim that they are fully funded to profitability.
Accelerating. Up from $241.6 million in FY24. The sequential leap in Q4 R&D ($78.6M vs $56.2M in Q3) reflects the heavy capital commitment required to transition Revuforj into frontline trials like REVEAL-ND and EVOLVE-2.
Guidance
Stable. Syndax guides for ~$400M in cash-based operating expenses (excluding an estimated $50M in non-cash stock compensation). For context, FY25 total GAAP OpEx was $445.4M. This implies roughly flat or slightly decelerating operational spending, which is vital to ensuring the current $394M cash pile lasts until cash-flow break-even.
Accelerating. Management reiterated that the current cash base, combined with rapidly scaling product and collaboration revenue, removes the need for further dilutive equity raises. With Q4 revenue approaching $70M, quarterly break-even could foreseeably arrive within 4-6 quarters if current growth rates hold.
Key Questions
Post-Transplant Restart Rates
In prior quarters, the Revuforj post-transplant restart rate was hovering around 35-40%. How has this metric evolved with the larger Q4 patient cohort, and what specific commercial actions are being taken to drive this towards your 70-90% target?
NPM1m Patient Mix
With the 35% jump in Revuforj prescriptions in Q4, can you provide color on the split between the established KMT2A indication and the newly approved NPM1m indication?
Niktimvo Profit Margins
Your Q4 collaboration revenue represented almost 35% of Incyte's reported net sales for Niktimvo. Where do you expect this margin percentage to stabilize as the launch matures and commercial infrastructure costs flatten?
IPF Trial Confidence
Given the history of trial failures in IPF, what specific early biomarkers or real-world data from your cGVHD cohorts give you confidence heading into the MAXPIRe Phase 2 data readout in Q4 2026?